7月28日上榜港股通成交活跃榜个股中，微创医疗为近一个月首次上榜。 证券时报•数据宝统计显示，7月28日港股通（包括沪市港股通及深市港股通）成交活跃股合计成交 332.01亿港元，占当日港股通成交金额的24.88%，净买入金额32.47亿港元。 7月28日港股通成交活跃股榜单 上榜的成交活跃股中，阿里巴巴-W成交额为47.61亿港元，成交金额居首；其次是中芯国际、中国人 寿，成交金额分别为39.52亿港元、38.95亿港元。 | 证券代码 | 证券简称 | 成交金额 | 净买入金额 | 近一个月上榜次数 | 最新收盘价 | 日涨跌幅（%） | | --- | --- | --- | --- | --- | --- | --- | | | | （亿港元） | （亿港元） | | （港元） | | | 00700 | 腾讯控股 | 38.39 | 5.98 | 20 | 555.500 | 0.91 | | 00981 | 中芯国际 | 39.52 | 1.55 | 20 | 53.100 | 0.66 | | 01788 | 国泰君安国际 | 35.70 | 0.53 | 20 | 6.720 | 9.45 | ...

Core Viewpoint - The entry of Shanghai state-owned enterprise Shanshi Capital as a strategic shareholder in MicroPort Medical is expected to enhance the company's core business development and governance, while addressing past controversies related to shareholder interests and capital operations [1][2]. Group 1: Strategic Investment and Governance - Shanshi Capital's investment is anticipated to provide low-cost funding support and improve the company's financing capabilities due to its state-owned background [2]. - The involvement of state capital is expected to create a balance of power within the board, allowing for direct participation in strategic decision-making and enhancing alignment of interests [2]. - The company aims to focus resources on core business areas, potentially reducing governance disputes arising from previous spin-off attempts [2]. Group 2: Business Expansion and Financial Performance - MicroPort Medical has expanded its business into various fields, including cardiovascular intervention and orthopedic medical devices, since its listing in September 2010 [2]. - Despite revenue growth from 4.233 billion yuan to 6.734 billion yuan between 2020 and 2023, the company has faced significant losses, with a net loss of 3.383 billion yuan in 2023 [4]. - The company has been under pressure to improve its financial situation, leading to a focus on reducing research and development expenses and optimizing operations [8][11]. Group 3: Debt and Financial Strategy - The company's current liabilities surged from over 3 billion yuan to 9.6 billion yuan from 2020 to 2023, indicating increased short-term debt risks [6]. - In April 2024, MicroPort Medical secured a loan of up to 200 million USD, with a portion tied to performance agreements that limit future losses [7][8]. - The company has initiated a shift from research-focused strategies to a more marketing-oriented approach, significantly reducing operational costs and employee numbers [11]. Group 4: Future Outlook and Challenges - For the first half of 2025, MicroPort Medical anticipates a revenue decline of no more than 4%, with expected losses of up to 110 million USD, which aligns with previous performance agreements [14]. - The effectiveness of state capital's involvement in improving the company's performance and governance remains uncertain [14].

Market Overview - On July 28, the Hang Seng Index rose by 0.68%, closing at 25,562.13 points, with a total net inflow of southbound funds through the Stock Connect amounting to HKD 9.253 billion [1] Trading Activity - The total trading volume for the Stock Connect on July 28 was HKD 133.454 billion, with a net buy of HKD 9.253 billion [1] - The Shanghai Stock Connect recorded a trading volume of HKD 85.075 billion and a net buy of HKD 6.338 billion, while the Shenzhen Stock Connect had a trading volume of HKD 48.378 billion and a net buy of HKD 2.915 billion [1] Active Stocks - In the Shanghai Stock Connect, the top traded stock was Alibaba-W with a transaction amount of HKD 3.322 billion, followed by China Life and Tencent Holdings with transaction amounts of HKD 2.878 billion and HKD 2.590 billion, respectively [1] - China Life had the highest net buy amount of HKD 1.007 billion, with its stock price increasing by 1.76%. Conversely, China Ping An had the highest net sell amount of HKD 214 million, with its stock price rising by 3.49% [1] Shenzhen Stock Connect Highlights - In the Shenzhen Stock Connect, the top traded stock was SMIC with a transaction amount of HKD 1.615 billion, followed by Alibaba-W and Xiaomi Group with transaction amounts of HKD 1.438 billion and HKD 1.416 billion, respectively [2] - China Ping An recorded the highest net buy amount of HKD 462 million, with its stock price increasing by 3.49%. Meituan had the highest net sell amount of HKD 281 million, with its stock price declining by 0.54% [2] Summary of Active Stocks - A summary table of the top active stocks includes: - Alibaba-W: Transaction amount HKD 3.322 billion, net buy HKD 797 million, daily change +2.20% [2] - China Life: Transaction amount HKD 2.878 billion, net buy HKD 1.007 billion, daily change +1.76% [2] - Tencent Holdings: Transaction amount HKD 2.590 billion, net buy HKD 749 million, daily change +0.91% [2] - SMIC: Transaction amount HKD 1.615 billion, net buy HKD 453 million, daily change +0.66% [2] - China Ping An: Transaction amount HKD 1.534 billion, net sell HKD 214 million, daily change +3.49% [2]

Core Insights - On July 28, 2025, Alibaba-W (09988), China Life (02628), and Tencent Holdings (00700) were the top three companies by trading volume in the southbound trading of the Stock Connect, with trading amounts of 3.322 billion, 2.878 billion, and 2.590 billion respectively [1] - In the Shenzhen-Hong Kong Stock Connect, SMIC (00981), Alibaba-W (09988), and Xiaomi Group-W (01810) led the trading volume, with amounts of 1.615 billion, 1.438 billion, and 1.416 billion respectively [1] Southbound Trading - Hong Kong Stock Connect - Top active companies by trading amount: - Alibaba-W (09988): 3.322 billion, net inflow of 79.7145 million [2] - China Life (02628): 2.878 billion, net inflow of 1.007 billion [2] - Tencent Holdings (00700): 2.590 billion, net inflow of 74.9 million [2] - Other notable companies include: - Guotai Junan International (01788): 2.588 billion, net outflow of 37.9091 million [2] - SMIC (00981): 2.337 billion, net inflow of 1.1 billion [2] Southbound Trading - Shenzhen-Hong Kong Stock Connect - Top active companies by trading amount: - SMIC (00981): 1.615 billion, net inflow of 45.3191 million [2] - Alibaba-W (09988): 1.438 billion, net inflow of 358 million [2] - Xiaomi Group-W (01810): 1.416 billion, net outflow of 187 million [2] - Other notable companies include: - Tencent Holdings (00700): 1.249 billion, net outflow of 152 million [2] - Meituan-W (03690): 1.186 billion, net outflow of 281 million [2]

7月28日港股市场，北水成交净买入92.53亿港元，其中港股通(沪)成交净买入63.38亿港元，港股通(深) 成交净买入29.15亿港元。 北水净买入最多的个股是中国人寿(02628)、建设银行(00939)、腾讯(00700)。 | 股票名称 | 买入额 | 卖出额 | 买卖总额 | | --- | --- | --- | --- | | | | | 净流入 | | 阿里巴巴-W | 17.01亿 | 16.21亿 | 33.22 乙 | | HK 09988 | | | +7971.45万 | | 中国人寿 | 19.42 Z | 9.36亿 | 28.78亿 | | HK 02628 | | | +10.07 Z | | 腾讯控股 | 16.69 亿 | 9.20亿 | 25.90亿 | | HK 00700 | | | +7.49 Z | | 国泰君安 ... | 12.75 乙 | 13.13亿 | 25.88亿 | | HK 01788 | | | -3790.91万 | | 中芯国际 | 12.23 乙 | 11.14 乙 | 23.37亿 | | HK 00981 | | | +1.10 Z ...

Group 1 - Otsuka Medical Devices Co., Ltd. has agreed to sell approximately 291 million shares of MicroPort Medical to various buyers, including Shanghai Shenshi Capital and We'Tron Capital Limited, which represents 15.7% of MicroPort's total share capital [1] - Following the announcement, MicroPort's stock price surged, opening up 14.99% and closing with a 4.75% increase, giving it a market capitalization of approximately HKD 21.2 billion [1] - This transaction will reduce Otsuka's stake in MicroPort from 20.7% to 5%, marking the first time since 2004 that Otsuka will not be the largest shareholder [1] Group 2 - Otsuka's initial investment in MicroPort dates back to 2004 when it invested USD 18 million for a 40% stake, which has since appreciated significantly, yielding a return of nearly 31 times [2] - The current shareholder structure of MicroPort includes We'Tron Capital Limited and the Jinshan Foundation as the second and third largest shareholders, holding a combined 37.5% [2] - The fourth and fifth largest shareholders are Shanghai ZJ Hi-Tech Investment Corporation and Shanghai Zhangjiang Health Products Holdings, with a combined stake of 16.0% [2] Group 3 - The buyer, Shanghai Shenshi Capital, is a fund management platform fully controlled by the Shanghai State-owned Assets Supervision and Administration Commission, indicating renewed interest in the biopharmaceutical sector [3] - MicroPort has faced financial challenges, reporting net losses over the past five years, with losses of CNY 1.248 billion, 1.763 billion, 3.04 billion, 3.383 billion, and 1.539 billion from 2020 to 2024 [3] - Despite the losses, MicroPort's revenue has shown consistent growth, increasing from CNY 4.233 billion in 2020 to CNY 7.412 billion in 2024 [3]

Group 1: Hong Kong Stock Market Highlights - New China Life Insurance (01336) rose over 5%, reaching a historical high, while China Life (2628.HK) increased by 4.4%, AIA (1299.HK) by 3.5%, and China Pacific Insurance (2601.HK) by nearly 2% following the release of the 2Q25 predetermined interest rate of 1.99% by the insurance industry association [1] - Heng Rui Pharmaceutical (1276.HK) opened up 10.65% after announcing a global exclusive licensing agreement with GSK for the HRS-9821 project, excluding mainland China and certain regions [1] - Guangshen Railway (00525.HK) saw a peak increase of over 9% after signing a cooperation agreement for the Guangzhou East Station renovation project, with a total investment of approximately 16.66 billion yuan [1] Group 2: Other Notable Stock Movements - MicroPort Medical (00853.HK) surged over 8% as major shareholders agreed to sell a total of 291 million shares to various buyers, including funds under Shanghai Industrial Capital [2] - China Tobacco Hong Kong (06055.HK) rose over 5% following the release of a draft management regulation for domestic duty-free tobacco products by the National Tobacco Monopoly Administration [2] - Shenghua Land (08106) saw its stock price soar over 200% after a share acquisition agreement was reached [2] - Jiufang Zhitu Holdings (09636) increased over 10% after announcing a profit forecast for the first half of the year, expecting a net profit of 830 to 870 million yuan, a turnaround from a net loss of 174 million yuan in the same period last year [2] - Lianlian Digital (02598) rose over 7% as a report highlighted the significant role of third-party payment institutions in cross-border and multi-currency settlement services [2] Group 3: Macau Gaming Sector Performance - Gaming stocks saw a general increase, with Amax Holdings (00880) up 10.39%, Melco International Development (00200) up 5.64%, and Sands China (01928) up 3.25%. UBS reported that the average daily gaming revenue in Macau for the past week was 657 million patacas, a slight decline due to typhoon impacts, but still showing a year-on-year growth of approximately 14% [3] Group 4: US Stock Market Highlights - AMD (AMD.US) rose 2.68% as it achieved a 50% market share in the server CPU market, matching Intel for the first time [4] - Newmont Corporation (NEM.US) increased by 6.89%, reporting a second-quarter earnings per share of $1.85, up from 73 cents year-on-year [5] - Berkshire Hathaway's holding Verisign (VRSN.US) rose 6.67% despite Q2 revenue falling short of market expectations, as the company raised its full-year revenue guidance [5] - Tesla (TSLA.US) increased by 3.52% with plans to launch Robotaxi services in San Francisco [6]

Core Viewpoint - The Hang Seng Healthcare Index (HSHCI) has shown positive performance, with significant increases in constituent stocks, indicating a favorable market environment for healthcare investments [3][4]. Group 1: Market Performance - As of July 28, 2025, the HSHCI rose by 0.64%, with notable gains from stocks such as MicroPort Medical (up 9.51%) and Eddy Health Holdings (up 3.93%) [3]. - The Hang Seng Healthcare ETF (513060) opened higher, increasing by 1.22% to a latest price of 0.66 yuan, and has accumulated a 0.92% rise over the past week [3]. - The ETF recorded a turnover of 0.79% during the trading session, with a transaction volume of 61.18 million yuan, and an average daily trading volume of 2.815 billion yuan over the past week, ranking first among comparable funds [3]. Group 2: Policy and Industry Outlook - The national procurement policy is expected to expand from pharmaceuticals to medical devices, potentially leading to performance reversals in high-value consumables and in vitro diagnostics sectors [4]. - The medical device sector is anticipated to benefit from a recovery in procurement activities this year, with expectations of an earnings turning point in the third quarter [4]. Group 3: ETF Performance Metrics - The latest size of the Hang Seng Healthcare ETF is 7.656 billion yuan, placing it in the top third among comparable funds [4]. - The ETF has seen a net value increase of 29.88% over the past two years, with a maximum monthly return of 28.34% since inception [4]. - The ETF's Sharpe ratio for the past year is 2.30, indicating strong risk-adjusted returns [4]. Group 4: Valuation and Tracking Accuracy - The HSHCI's latest price-to-earnings ratio (PE-TTM) is 31.72, which is below 84.29% of the historical data over the past three years, suggesting a low valuation [6]. - The ETF has the highest tracking accuracy among comparable funds, with a tracking error of 0.060% over the past year [6]. - The top ten weighted stocks in the HSHCI account for 60.54% of the index, including companies like BeiGene and WuXi Biologics [6].

Investment Rating - The report does not explicitly state an investment rating for the industry, but it provides insights into market performance and trends [2][4]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.9%, underperforming the Wind All A index (2.21%) but outperforming the CSI 300 index [2][7]. - The medical research outsourcing segment experienced the highest growth at 8.29%, while chemical preparations and other biological products faced declines of -2.02% and -0.58%, respectively [2][8]. - The Quark Health model achieved a significant milestone by passing the written assessment for chief physician in 12 core disciplines, marking a rapid development phase for medical AI models in China [2][11]. - State-owned equity funds are actively acquiring stakes in pharmaceutical companies, with notable transactions including the acquisition of Kanghua Biological and a significant stake in MicroPort Medical [2][11]. Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector rose by 1.9% from July 21 to July 25, 2025, with medical research outsourcing leading the gains at 8.29% [2][7]. - Individual stocks such as Haitai Biological (46.9%), Zhendong Pharmaceutical (42.9%), and Saily Medical (31.7%) saw significant increases, while *ST Suwu (-22.3%) and Yong'an Pharmaceutical (-13.7%) faced notable declines [2][10]. Industry News and Key Company Announcements Important Industry Events - The National Medical Insurance Administration announced new measures to optimize drug procurement, emphasizing quality over lowest price and launching a nationwide drug price comparison tool [2][11]. Industry News - Shanghai Biopharmaceutical M&A Fund is set to acquire shares in MicroPort Medical, becoming a strategic shareholder [2][11]. - Kangfang Biologics' new indication application for Ivoris monoclonal antibody has been accepted by the National Medical Products Administration [2][11]. Company Announcements - WuXi Biologics reported a positive mid-year earnings forecast, expecting a 16% revenue increase and a 3.6% rise in gross margin [2][14]. - The Quark Health model's capabilities continue to align closely with human physicians, marking a significant advancement in AI healthcare applications [2][14]. - WuXi AppTec and other companies reported substantial revenue growth, with WuXi AppTec expecting over 60% growth in the first half of 2025 [2][14].

Core Viewpoint - Shanghai Shanshi Capital will become an important strategic shareholder of MicroPort Medical [2][4] Group 1: Shareholder Changes - MicroPort Medical announced on July 25 that it has received notice from Otsuka Medical Devices Co., Ltd. regarding the conditional sale of approximately 291 million shares [2] - The buyers include funds under Shanghai Shanshi Capital, We'Tron Capital Limited, and the company's management investment platform [2] Group 2: Strategic Importance - The board of MicroPort Medical believes that Shanshi Capital will play a crucial role as a strategic shareholder, leveraging its state-owned background and industry resources to support the company's core business expansion and potential strategic acquisitions [4] - Shanshi Capital, established as an active fund management platform under Shanshi Group, focuses on investment opportunities in strategic emerging industries such as biomedicine and green environmental protection [4] Group 3: Financial Context - MicroPort Medical, founded in 1998 and headquartered in Zhangjiang, Shanghai, is a leading innovative high-end medical device group in China, but has reported continuous losses for five consecutive years [4] - On July 25, MicroPort Medical's stock closed at HKD 10.94 per share, with a 4.59% increase, and has surged 34% over the last three trading days, bringing its latest market capitalization to HKD 20.2 billion [6]